ArticleGastroenterology and hepatology from bed to bench2025
Association between the Human Development Index and the burden of major gastrointestinal cancers: results from Global Burden of Disease 2021.
Article in Gastroenterology and hepatology from bed to bench, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Current burden, incidence trends, and future projections of pancreatic cancer in adults worldwide.Journal of global health · 2026Article
- Long-term effects of human development on the global burden of gallbladder and biliary tract cancer: a longitudinal multilevel analysis, 1990-2021.Gastroenterology and hepatology from bed to bench · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: To assess the longitudinal association between the Human Development Index (HDI) and the global burden of major gastrointestinal (GI) cancers from 1990 to 2021. Background: GI cancers contribute substantially to global incidence, mortality, and disability-adjusted life years (DALYs), with wide variation across HDI levels. Methods: Using Global Burden of Disease 2021 data, we analyzed age-standardized incidence (ASIR), mortality (ASMR), disability-adjusted life-year (ASDR), and tobacco-attributable mortality for colorectal, liver, pancreatic, and stomach cancers (1990-2021). Countries were classified as more developed (HDI ≥0.700) or less developed (HDI <0.700), and associations were assessed using longitudinal multilevel mixed-effects models and Spearman correlations. Results: In 2021, HDI was positively correlated with colorectal and pancreatic cancer burden, while liver cancer showed inverse associations only in less developed countries and stomach cancer only in more developed settings. For tobacco-attributable ASMR, associations were positive for colorectal and pancreatic cancers, non-significant for liver, and opposite for stomach (positive in less vs. inverse in more developed countries). Longitudinally (1990-2021), colorectal cancer showed a rising ASIR in both groups, but significantly divergent slopes for ASMR and ASDR, with declining rates in more developed countries and increasing rates in less developed countries. Liver cancer had significantly unfavorable slopes, with ASIR, ASMR, and ASDR increasing in more developed but declining in less developed settings. Pancreatic cancer exhibited increases in all measures, with significantly slower growth in more developed countries. Stomach cancer showed consistent declines across all measures, with considerably steeper reductions in more developed regions. Conclusion: Human development strongly shapes GI cancer burden, with divergent high- and low-HDI trends evident only in longitudinal analyses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.